Savara Inc (NASDAQ:SVRA) Stock Position Increased by EntryPoint Capital LLC

EntryPoint Capital LLC grew its position in Savara Inc (NASDAQ:SVRA) by 152.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 103,288 shares of the company’s stock after purchasing an additional 62,325 shares during the period. EntryPoint Capital LLC’s holdings in Savara were worth $317,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the company. Emerald Advisers LLC acquired a new position in Savara during the 4th quarter worth $7,161,000. Vanguard Group Inc. raised its stake in shares of Savara by 4.6% during the fourth quarter. Vanguard Group Inc. now owns 8,309,970 shares of the company’s stock valued at $25,512,000 after purchasing an additional 365,959 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new stake in Savara in the fourth quarter worth about $41,000. Rosalind Advisors Inc. bought a new position in Savara in the 4th quarter valued at about $8,151,000. Finally, Cibc World Markets Corp acquired a new position in Savara during the 4th quarter valued at about $33,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Savara Price Performance

Shares of NASDAQ:SVRA opened at $2.78 on Friday. The company has a market capitalization of $477.10 million, a PE ratio of -6.47 and a beta of 0.60. The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.70 and a current ratio of 17.70. The stock has a fifty day moving average of $2.72 and a 200-day moving average of $3.27. Savara Inc has a one year low of $2.26 and a one year high of $5.34.

Wall Street Analyst Weigh In

SVRA has been the subject of a number of research analyst reports. JMP Securities reaffirmed a “market outperform” rating and issued a $9.00 price target on shares of Savara in a research note on Thursday, December 19th. Wells Fargo & Company began coverage on Savara in a research report on Friday, December 20th. They issued an “overweight” rating and a $8.00 target price for the company. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $8.83.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.